118 related articles for article (PubMed ID: 10997818)
1. Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patients.
Theyer G; Ulsperger E; Baumgartner G; Raderer M; Hamilton G
Ann Oncol; 2000 Jul; 11(7):877-81. PubMed ID: 10997818
[TBL] [Abstract][Full Text] [Related]
2. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Dürer A; Theyer U; Haberl I; Ulsperger E; Baumgartner G; Hamilton G
Prostate; 1999 Oct; 41(2):71-7. PubMed ID: 10477903
[TBL] [Abstract][Full Text] [Related]
3. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Holub S; Dürer A; Andert S; Haberl I; Theyer U; Hamilton G
Br J Cancer; 1997; 75(10):1515-8. PubMed ID: 9166947
[TBL] [Abstract][Full Text] [Related]
4. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
[TBL] [Abstract][Full Text] [Related]
5. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
Pedraza R; Kwart AM
Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
[TBL] [Abstract][Full Text] [Related]
6. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.
Abrahamsson PA; Boccon-Gibod L; Morote J; de Jong IJ; Malmberg A; Neijber A; Albers P
Eur Urol Focus; 2017 Oct; 3(4-5):470-479. PubMed ID: 28753747
[TBL] [Abstract][Full Text] [Related]
7. Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer.
Bryant AK; McKay RR; Kader AK; Parsons JK; Einck JP; Kane CJ; Mundt AJ; Murphy JD; Rose BS
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1068-1076. PubMed ID: 30543857
[TBL] [Abstract][Full Text] [Related]
8. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
9. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
[TBL] [Abstract][Full Text] [Related]
10. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
11. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
[TBL] [Abstract][Full Text] [Related]
12. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
13. A new protocol for intermittent androgen suppression therapy of prostate cancer with unstable saddle-point dynamics.
Suzuki Y; Sakai D; Nomura T; Hirata Y; Aihara K
J Theor Biol; 2014 Jun; 350():1-16. PubMed ID: 24524858
[TBL] [Abstract][Full Text] [Related]
14. Current status of intermittent androgen suppression in the treatment of prostate cancer.
Theyer G; Hamilton G
Urology; 1998 Sep; 52(3):353-9. PubMed ID: 9730443
[TBL] [Abstract][Full Text] [Related]
15. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
Sato N; Gleave ME; Bruchovsky N; Rennie PS; Goldenberg SL; Lange PH; Sullivan LD
J Steroid Biochem Mol Biol; 1996 May; 58(2):139-46. PubMed ID: 8809195
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
Strum SB; Scholz MC; McDermed JE
Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
[TBL] [Abstract][Full Text] [Related]
18. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome.
Malone S; Perry G; Eapen L; Segal R; Gallant V; Dahrouge S; Crook J; Spaans JN
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):699-706. PubMed ID: 17379438
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of change in prostate-specific antigen and testosterone following withdrawal of androgen ablation after combination of radiation and hormone therapy].
Hashine K; Numata K; Azuma K; Sumiyoshi Y
Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):678-84. PubMed ID: 16363653
[TBL] [Abstract][Full Text] [Related]
20. Intermittent versus continuous androgen suppression for prostatic cancer.
Conti PD; Atallah AN; Arruda H; Soares BG; El Dib RP; Wilt TJ
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD005009. PubMed ID: 17943832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
